Switching from Wellbutrin XL 300 mg to Strattera 25 mg for Anxiety and ADHD
You should not abruptly switch from Wellbutrin XL 300 mg to Strattera 25 mg; instead, initiate Strattera while continuing Wellbutrin, then taper Wellbutrin after Strattera reaches therapeutic levels over 6-8 weeks. This approach minimizes symptom exacerbation during the transition period, particularly important given your dual indication of anxiety and ADHD.
Critical Context: Medication Selection Issues
Wellbutrin (bupropion) is a second-line agent at best for ADHD 1, and notably, bupropion can actually worsen anxiety 2, 3. If anxiety is a primary concern, continuing bupropion may be counterproductive. Strattera (atomoxetine) is FDA-approved for ADHD and has demonstrated efficacy in reducing both ADHD symptoms and comorbid anxiety 4.
Switching Protocol
Week 1-2: Initiation Phase
- Continue Wellbutrin XL 300 mg (do not discontinue) 5
- Start Strattera 25 mg once daily in the morning 6
- Monitor for initial side effects (nausea, somnolence, GI upset) which are common but typically transient 6
- Consider splitting the 25 mg dose (morning and evening) if GI side effects occur 6
Week 3-4: Strattera Titration
- Increase Strattera to target dose of 60-80 mg daily (1.2 mg/kg/day, maximum 100 mg) 6
- Continue Wellbutrin XL 300 mg
- Co-administration is safe: A pharmacokinetic study showed bupropion increases atomoxetine exposure 5.1-fold through CYP2D6 inhibition 7, but clinical trials demonstrate this combination can be used during switching without undue cardiovascular concerns, though BP and heart rate monitoring is necessary 8
Week 5-6: Wellbutrin Taper
- Begin tapering Wellbutrin XL: Reduce to 150 mg daily for 2 weeks 5
- Continue Strattera at therapeutic dose
- Monitor for any return of depressive symptoms
Week 7-8: Complete Transition
- Discontinue Wellbutrin XL after 2-week taper
- Continue Strattera monotherapy
- Full therapeutic effect of Strattera requires 6-8 weeks minimum 6, 8, so evaluate efficacy only after this period
Important Safety Considerations
Cardiovascular Monitoring
- Check BP and heart rate at each visit during the switching period 9
- Atomoxetine can increase HR and BP, though typically mild (1-2 bpm, 1-4 mmHg) 9
- Obtain cardiac history before initiating; if risk factors present, consider ECG 9
Psychiatric Monitoring
- Monitor closely for suicidal ideation, especially in the first few months of atomoxetine treatment 6
- This is particularly important given the FDA black box warning for atomoxetine in children/adolescents, though adult data did not show increased risk 6
- Assess for worsening anxiety or agitation in weeks 1-2 of atomoxetine initiation
Drug Interaction Alert
Bupropion is a potent CYP2D6 inhibitor 7, which will significantly increase atomoxetine levels during co-administration. This means:
- You may experience stronger effects (both therapeutic and adverse) from the 25 mg Strattera dose initially
- After discontinuing bupropion, atomoxetine levels will decrease, potentially requiring dose adjustment upward
- Approximately 7% of the population are poor CYP2D6 metabolizers and will have higher atomoxetine levels regardless 6
Expected Timeline for Symptom Improvement
- ADHD symptoms: Expect gradual improvement over 6-12 weeks with atomoxetine 6, much slower than stimulants
- Anxiety symptoms: May improve within 4-6 weeks 4
- Around-the-clock coverage: Unlike Wellbutrin's once-daily effect, atomoxetine provides consistent symptom control throughout waking hours and into evening 6, 8
Alternative Consideration
If anxiety is the primary concern, consider whether atomoxetine is the optimal choice. Guidelines suggest SSRIs as first-line for anxiety disorders 10, and stimulants remain first-line for ADHD 6, 9. Atomoxetine is recommended as second-line for ADHD 6 but has demonstrated efficacy for comorbid anxiety 4. The combination of an SSRI plus a stimulant may ultimately provide superior outcomes for both conditions 10, 1, though atomoxetine monotherapy is a reasonable approach to avoid polypharmacy.
Common Pitfalls to Avoid
- Do not abruptly stop Wellbutrin: While discontinuation syndrome is less common with bupropion than SSRIs, gradual taper is recommended 5
- Do not expect rapid ADHD improvement: Atomoxetine requires 6-8 weeks minimum for full effect 8, 11, unlike stimulants which work within hours
- Do not crush or split Strattera capsules: Must be swallowed whole 6
- Do not evaluate treatment failure prematurely: Studies show 50% of methylphenidate non-responders will respond to atomoxetine, but adequate trial duration is essential 8